Ondansetron Injection USP 2 mg/ml

Therapeutic Class:

Dosage Forms:

Brand Name: Onkatil-2

How it works?

Ondansetron Injection USP 2 mg/ml is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention and treatment of post-operative nausea and vomiting (PONV).

The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The route of administration and dose of Ondansetron should be flexible in the range of 8-32 mg a day and selected as shown below.
Emetogenic chemotherapy and radiotherapy
For patients receiving emetogenic chemotherapy or radiotherapy Ondansetron can be given either by oral or intravenous administration.
For most patients receiving emetogenic chemotherapy or radiotherapy, Ondansetron 8 mg should be administered as a slow intravenous injection (in not less than 30 seconds) or as a short-time intravenous infusion over 15 minutes immediately before treatment, followed by 8 mg orally twelve hourly.
To protect against delayed or prolonged emesis after the first 24 hours, oral treatment with Ondansetron should be continued for up to 5 days after a course of treatment.
Highly emetogenic chemotherapy
For patients receiving highly emetogenic chemotherapy, e.g. high-dose cisplatin, Ondansetron can be given either by oral, rectal or intravenous administration. Ondansetron has been shown to be equally effective in the following dose schedules over the first 24 hours of chemotherapy:
A single dose of 8 mg by slow intravenous injection (in not less than 30 seconds) immediately before chemotherapy.
A dose of 8 mg by slow intravenous injection (in not less than 30 seconds) immediately before chemotherapy, followed by two further intravenous injections (in not less than 30 seconds) of 8 mg four hours apart, or by a constant infusion of 1 mg/hour for up to 24 hours.
A maximum initial intravenous dose of 16 mg diluted in 50-100 ml of saline or other compatible infusion fluid and infused over not less than 15 minutes immediately before chemotherapy. The initial dose of Ondansetron may be followed by two additional 8 mg intravenous doses (in not less than 30 seconds) four hours apart.
A single dose greater than 16 mg must not be given due to dose dependent increase of QT-prolongation risk . The selection of dose regimen should be determined by the severity of the emetogenic challenge.
The efficacy of Ondansetron in highly emetogenic chemotherapy may be enhanced by the addition of a single intravenous dose of dexamethasone sodium phosphate, 20 mg administered prior to chemotherapy.
To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with Ondansetron should be continued for up to 5 days after a course of treatment.

Headache, Uncommon: Seizures, movement disorders, Rare: Dizziness predominantly during rapid IV administration, Constipation, Local IV injection site reactions.

Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5HT3 receptor antagonists. Respiratory events should be treated symptomatically and clinicians should pay particular attention to them as precursors of hypersensitivity reactions.
Ondansetron prolongs the QT interval in a dose-dependent manner. Avoid ondansetron in patients with congenital long QT syndrome. Ondansetron should be administered with caution to patients who have or may develop prolongation of QTc, including patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias or patients taking other medicinal products that lead to QT prolongation or electrolyte abnormalities.
Hypokalemia and hypomagnesemia should be corrected prior to ondansetron administration.
Concomitant treatment with ondansetron and other serotonergic drugs is clinically warranted, appropriate observation of the patient is advised.
As ondansetron is known to increase large bowel transit time, patients with signs of sub-acute intestinal obstruction should be monitored following administration.
In patients with adenotonsillar surgery prevention of nausea and vomiting with ondansetron may mask occult bleeding. Therefore, such patients should be followed carefully after ondansetron.
Paediatric patients receiving ondansetron with hepatotoxic chemotherapeutic agents should be monitored closely for impaired hepatic function.

Store below 30oC and protect from light.
Keep out of reach of children.

Onkatil-2 injection is available as 2 ml in clear glass ampoule. Such 10 glass ampoules in unit carton with pack insert.

interested? let’s talk.

Contact us directly to receive full information on the product, the formulation, the science behind it, stability data, and more. Our Business Development Manager is a click away.

F. A. Q

Frequently Asked Questions

Questions are useful tools, they open lines of communication; give us information; improve interactions, facilitate analysis, and many more.

We have below MOQ for:

  1. Tablet, Capsules & Softgel: 200000 Units
  2. Ampoules : 100000 Units
  3. Vials: 10000 Units
  4. Ointment and Cream: 15000 Units
  5. Suppository: 50000 Units
  6. Syrup and Liquid: 10000 Units
  7. Sachets : 50000 Units

We do ready the product within 45-60 days after product artwork confirmation from your side. So, including transit time you can get the product within 90 days maximum, either by Air or Sea route.

A product's “shelf life” generally means the length of time you can expect a product to look and act as expected and to stay safe for use. This length of time varies, depending on the type of product, how it is used, and how it is stored.

Our products come with a minimum of 24 months to a maximum of 36 months of shelf life.

For, Primary packaging we use aluminium foil with 20 to 50 micron size and PVC foil with 350 to 400 micron depending on product characteristics and stability.

For, Secondary packing we do use 300 to 400 GSM FFB Card board.

For, Tertiary packing we do us 7 ply 150 GSM corrugated boxes to prevent the damage during transits.

Yes, we do have available for all dossier documents according to GMP guidelines for the respective country. We do also provide COPP and Free sale certificates (FSC) on demand to customers for special import permit type of commercial orders.